We are a biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. We are utilizing our proprietary FUSION™ System to discover and design a pipeline of next-generation covalent-binding small molecule medicines. We aim to have an outsized impact on the treatment of disease for the patients we serve. We aim to cure.
We are a biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs including greater target selectivity, lower drug exposure and the ability to drive a deeper, more durable response.